US-based GenScript Biotech, and China-based startup T-Maximum Biotech, a biotechnology company pioneering universal cell therapies, have formed a strategic collaboration agreement to enable the development of T-Maximum's development CAR-T cell therapy using GenScript's CRISPR nucleic acid reagents.

GenScript will provide T-Maximum Biotech with various CRISPR reagents to support the development of its universal CAR-T products from discovery to commercialisation. The partnership with GenScript will support T-Maximum Biotech's strategic development plan to progress multiple products to the Phase II clinical research stage and deliver products to market within the next five years.

T-Maximum Biotech is a clinical-stage cell therapy development company with core technology published in top journals such as Nature, Nature Biotechnology, Nature Methods, and Cell. Its universal CAR-T cell therapy product, MT027, is being developed for the treatment of recurrent high-grade gliomas. The startup uses the CRISPR system and electroporation RNP technology to knock out the TRAC and HLA genes, eliminating GVHD and TCR receptor signal interference, reducing rejection reactions, and prolonging the survival time of CAR-T cells in the body.

In February of this year, based on comprehensive preclinical research and positive results from investigator-initiated clinical studies (IIT), T-Maximum Biotech's MT027 obtained FDA Orphan Drug Designation (ODD) certification — a breakthrough milestone in the company's mission to "solve the treatment of diseases with no available drugs."